ATE288268T1 - Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden - Google Patents

Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden

Info

Publication number
ATE288268T1
ATE288268T1 AT99960663T AT99960663T ATE288268T1 AT E288268 T1 ATE288268 T1 AT E288268T1 AT 99960663 T AT99960663 T AT 99960663T AT 99960663 T AT99960663 T AT 99960663T AT E288268 T1 ATE288268 T1 AT E288268T1
Authority
AT
Austria
Prior art keywords
glp
receptor
peptide
antagonists
methods
Prior art date
Application number
AT99960663T
Other languages
English (en)
Inventor
Larry Kenneth Truesdale
Richard A Bychowski
Javier Gonzalez
Atsuo Kuki
Ranjan Jagath Rajapakse
Min Teng
Dan Kiel
Daljit S Dhanoa
Yufeng Hong
Tso-Sheng Chou
Anthony L Ling
Michael David Johnson
Vlad Edward Gregor
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Application granted granted Critical
Publication of ATE288268T1 publication Critical patent/ATE288268T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99960663T 1998-12-10 1999-12-08 Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden ATE288268T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11173698P 1998-12-10 1998-12-10
PCT/US1999/029065 WO2000033839A1 (en) 1998-12-10 1999-12-08 Non-peptide antagonists of glp-1 receptor and methods of use

Publications (1)

Publication Number Publication Date
ATE288268T1 true ATE288268T1 (de) 2005-02-15

Family

ID=22340176

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960663T ATE288268T1 (de) 1998-12-10 1999-12-08 Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden

Country Status (14)

Country Link
US (1) US6469021B1 (de)
EP (1) EP1137413B1 (de)
JP (1) JP2002531501A (de)
KR (1) KR20010089563A (de)
AT (1) ATE288268T1 (de)
AU (1) AU758968B2 (de)
BR (1) BR9916965A (de)
CA (1) CA2350887A1 (de)
DE (1) DE69923587T2 (de)
ES (1) ES2233089T3 (de)
NZ (1) NZ511698A (de)
PT (1) PT1137413E (de)
WO (1) WO2000033839A1 (de)
ZA (1) ZA200104128B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001254621A1 (en) 2000-05-05 2001-11-20 K.U. Leuven R And D Critical illness neuropathy
AU2002221222A1 (en) * 2000-12-04 2002-06-18 Biovitrum Ab Novel method and use
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
WO2003066084A1 (en) * 2002-02-07 2003-08-14 Novo Nordisk A/S Use of glp-1 compound for treatment of critically ill patients
CA2474460C (en) * 2002-02-13 2009-12-22 F. Hoffmann-La Roche Ag Pyridine- and quinoline-derivatives
CN100503607C (zh) 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
EP2818181B1 (de) * 2007-01-08 2018-10-24 The Trustees Of The University Of Pennsylvania Zusammensetzungen und medizinische Verwendungen davon
MX2010003149A (es) * 2007-09-20 2010-11-10 D2E Llc Derivados que contienen fluor de pirido[4,3-b]indoles hidrogenados con propiedades neuroprotectoras y de mejoramiento de cognicion, proceso de preparacion y uso.
WO2009067233A1 (en) * 2007-11-20 2009-05-28 Millennium Pharmaceuticals, Inc. Beta carbolines and uses thereof
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
RS62368B1 (sr) 2015-05-22 2021-10-29 Univ Leland Stanford Junior Lečenje postbarijatrijske hipoglikemije eksendinom(9-39)
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
BR112019010236A2 (pt) 2016-11-21 2019-08-20 Eiger Biopharmaceuticals, Inc formulações tamponadas de exendina (9-39)
CN111362937B (zh) * 2020-03-06 2021-06-22 贵州医科大学 N-芳基-β-卡波林类衍生物及其用途
IL300048A (en) * 2020-07-23 2023-03-01 Merck Patent Gmbh Heterocyclic compounds with three rings, their preparation and use
US20230390250A1 (en) * 2020-10-30 2023-12-07 Robin Elaine DUNCAN Modulation of glucagon-like peptide 1 and uses thereof
JP2025534686A (ja) 2022-10-14 2025-10-17 ハンミ ファーマシューティカル カンパニー リミテッド 新規なglp-1レセプターアンタゴニスト及びそれを含む先天性高インスリン症又は低血糖症の予防又は治療用薬学的組成物
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5644296A (en) * 1995-05-05 1996-11-21 Novo Nordisk A/S Novel heterocyclic chemistry

Also Published As

Publication number Publication date
EP1137413A2 (de) 2001-10-04
WO2000033839B1 (en) 2000-09-28
JP2002531501A (ja) 2002-09-24
US6469021B1 (en) 2002-10-22
NZ511698A (en) 2003-09-26
AU1751800A (en) 2000-06-26
KR20010089563A (ko) 2001-10-06
DE69923587D1 (de) 2005-03-10
DE69923587T2 (de) 2005-06-23
WO2000033839A1 (en) 2000-06-15
EP1137413B1 (de) 2005-02-02
ZA200104128B (en) 2002-05-21
ES2233089T3 (es) 2005-06-01
CA2350887A1 (en) 2000-06-15
EP1137413A4 (de) 2002-06-26
PT1137413E (pt) 2005-05-31
BR9916965A (pt) 2001-11-06
AU758968B2 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
DE69923587D1 (de) Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
ES2154167A1 (es) Aminoderivados ciclicos antagonistas del receptor ccr-3.
IL155806A0 (en) Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
MXPA02012271A (es) Nuevos compuestos que poseen actividad antibacteriana, antifungal o antitumor.
MY137457A (en) Cyclic peptides having melanocortin-4 receptor agonist activity
IL139956A0 (en) Conformationally constrained backbone cyclized somatostatin analogs
MXPA02009773A (es) Derivados de indolin-2-ona y su uso como ligandos de receptores de ocitocina.
DE69935670D1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
ATE468853T1 (de) Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
DK1208111T3 (da) Gener der koder for insekt-odorantreceptorer og anvendelser deraf
DE69906345D1 (de) Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
AU4981500A (en) Cancer treatment with endothelin receptor antagonists
BR9909522A (pt) Ligandos do receptor 5-ht1 azabicìclicos
GR950300029T1 (en) Dna encoding a human serotonin receptor (5-ht4b)a nd uses thereof.
MY127385A (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperlasia
PL364358A1 (en) Receptor in the edb fibronectin domain (ii)
PT1273572E (pt) Piperazinas substituidas com tiofeno uteis no tratamento da hiperplasia prostatica benigna
NO20002408L (no) 5-HT1F antagonister
MXPA01002798A (es) Antagonistas del receptor acoplado a la proteina g.
AU4136797A (en) Novel semaphorin gene: semaphorin y
GB0011071D0 (en) Organic compounds
DE60032161D1 (de) P-glycoproteine und ihre verwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1137413

Country of ref document: EP

REN Ceased due to non-payment of the annual fee